Global biotechnology company Alvotech (NASDAQ: ALVO), which develops and manufactures biosimilar medicines, said on Monday it has signed supply and commercialisation agreements with Sandoz Group AG (SIX: SDZ), a generics and biosimilars company based in Switzerland, covering multiple biosimilar candidates in Canada and in Australia and New Zealand.

In Canada, the deal covers one ophthalmology biosimilar supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, it includes three biosimilar candidates across immunology and gastroenterology in multiple formulations.

Sandoz will lead regulatory filings, commercialisation and distribution in the territories, while Alvotech will retain responsibility for development, global clinical activities and manufacturing, and will supply finished products to Sandoz under exclusive supply arrangements.

The agreements are intended to support patient access following regulatory approvals and market launches across the regions.